title: Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
authors.forename: Saurav
authors.initials: S
authors.lastname: Chatterjee
authors.forename: Subhankar
authors.initials: S
authors.lastname: Maitra
authors.forename: Anasua
authors.initials: A
authors.lastname: Chakraborty
mesh_terms: D050197:Atherosclerosis / Q000150:complications*; D005260:Female; D006470:Hemorrhage / Q000401:mortality*; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D013927:Thrombosis / Q000188:drug therapy*; D013988:Ticlopidine / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine